Arena Pharma ARNA today provided an update on Eisai Inc.'s marketing activities for
BELVIQ^® (lorcaserin HCl) as the US launch campaign enters its consumer phase.
Beginning this month, full-page announcements communicating the availability
of BELVIQ are being placed in major US magazines, including O, The Oprah
Magazine. These announcements are intended to educate consumers about BELVIQ
as a treatment option for weight loss and weight maintenance. In addition,
Eisai recently launched the BELIEVE EVERYDAY SUPPORT^SM program to provide
comprehensive support and savings for patients treated with BELVIQ. Patients
can enroll in the program at BelieveSupport.com. For Eisai's announcement with
additional details about the program, click here.
"Patient awareness and education about treatment options is an important
component of the patient/physician relationship," said Jack Lief, Arena's
President and Chief Executive Officer. "Eisai's consumer-focused efforts will
complement their comprehensive healthcare professional education initiatives
already underway."
Eisai is responsible for the marketing and distribution of BELVIQ in the
United States under its agreement with Arena.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in